Drug Profile
Hib vaccine conjugate - GSK
Alternative Names: HiberixLatest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Conjugate vaccines; Haemophilus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilus infections
Most Recent Events
- 01 Jul 2013 GlaxoSmithKline completes a phase III trial in healthy infants in USA (NCT01000974)
- 19 Aug 2009 Registered for Haemophilus infections in USA (IM)